These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19199907)

  • 1. Targeted therapies for prostate cancer against the prostate specific membrane antigen.
    Elsässer-Beile U; Bühler P; Wolf P
    Curr Drug Targets; 2009 Feb; 10(2):118-25. PubMed ID: 19199907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-drug conjugates targeting prostate-specific membrane antigen.
    Olson WC; Israel RJ
    Front Biosci (Landmark Ed); 2014 Jan; 19(1):12-33. PubMed ID: 24389170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Advances in prostate-specific membrane antigen targeted therapies for prostate cancer].
    Wang W; Mo ZN
    Zhonghua Nan Ke Xue; 2010 Jun; 16(6):547-51. PubMed ID: 20608362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-Specific Membrane Antigen-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer.
    Teo MY; Morris MJ
    Cancer J; 2016; 22(5):347-352. PubMed ID: 27749329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the prostate-specific membrane antigen for prostate cancer therapy.
    Bühler P; Wolf P; Elsässer-Beile U
    Immunotherapy; 2009 May; 1(3):471-81. PubMed ID: 20635963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
    Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
    Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.
    Huang X; Bennett M; Thorpe PE
    Prostate; 2004 Sep; 61(1):1-11. PubMed ID: 15287089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
    Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
    Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
    Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
    Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.
    Bander NH; Nanus DM; Milowsky MI; Kostakoglu L; Vallabahajosula S; Goldsmith SJ
    Semin Oncol; 2003 Oct; 30(5):667-76. PubMed ID: 14571414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies and prostate-specific membrane antigen.
    Chang SS
    Curr Opin Investig Drugs; 2004 Jun; 5(6):611-5. PubMed ID: 15242249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen.
    Slovin SF
    Expert Opin Ther Targets; 2005 Jun; 9(3):561-70. PubMed ID: 15948673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
    DiPippo VA; Olson WC; Nguyen HM; Brown LG; Vessella RL; Corey E
    Prostate; 2015 Feb; 75(3):303-13. PubMed ID: 25327986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What's in a Label? Radioimmunotherapy for metastatic prostate cancer.
    Simone CB; Hahn SM
    Clin Cancer Res; 2013 Sep; 19(18):4908-10. PubMed ID: 23926229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.
    Ma Q; Safar M; Holmes E; Wang Y; Boynton AL; Junghans RP
    Prostate; 2004 Sep; 61(1):12-25. PubMed ID: 15287090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer.
    Murga JD; Moorji SM; Han AQ; Magargal WW; DiPippo VA; Olson WC
    Prostate; 2015 Feb; 75(3):242-54. PubMed ID: 25327687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiolabeled J591 antibody delivers lethal hit to advance prostate cancers in a phase I trail.
    Cancer Biol Ther; 2004 Aug; 3(8):699-700. PubMed ID: 15754442
    [No Abstract]   [Full Text] [Related]  

  • 18. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice.
    Vallabhajosula S; Smith-Jones PM; Navarro V; Goldsmith SJ; Bander NH
    Prostate; 2004 Feb; 58(2):145-55. PubMed ID: 14716739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
    Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
    Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.
    Bander NH; Trabulsi EJ; Kostakoglu L; Yao D; Vallabhajosula S; Smith-Jones P; Joyce MA; Milowsky M; Nanus DM; Goldsmith SJ
    J Urol; 2003 Nov; 170(5):1717-21. PubMed ID: 14532761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.